Nongenomic Mechanisms of PTEN Regulation by Fata, Jimmie E. et al.
City University of New York (CUNY)
CUNY Academic Works
Publications and Research College of Staten Island
March 2012
Nongenomic Mechanisms of PTEN Regulation
Jimmie E. Fata
CUNY College of Staten Island
Shawon Debnath
CUNY College of Staten Island
Edmund C. Jenkins
CUNY College of Staten Island
Marcia V. Fournier
University of Massachusetts
How does access to this work benefit you? Let us know!
Follow this and additional works at: http://academicworks.cuny.edu/si_pubs
This Article is brought to you for free and open access by the College of Staten Island at CUNY Academic Works. It has been accepted for inclusion in
Publications and Research by an authorized administrator of CUNY Academic Works. For more information, please contact
AcademicWorks@cuny.edu.
Recommended Citation
Fata, J. E., Debnath, S., Jenkins, E. C. & Fournier, M. V. (2012). Nongenomic Mechanisms of PTEN Regulation. International Journal
of Cell Biology, 2012, 379685. doi:10.1155/2012/379685.
Hindawi Publishing Corporation
International Journal of Cell Biology
Volume 2012, Article ID 379685, 10 pages
doi:10.1155/2012/379685
Review Article
Nongenomic Mechanisms of PTEN Regulation
Jimmie E. Fata,1, 2, 3 Shawon Debnath,1, 3 Edmund C. Jenkins Jr.,1, 4 and Marcia V. Fournier5
1Department of Biology, College of Staten Island, 2800 Victory Boulevard, Staten Island, NY 10314, USA
2Biology Doctoral Program, City University of New York Graduate Center, 365 Fifth Avenue, New York, NY 10016, USA
3Biochemistry Doctoral Program, City University of New York Graduate Center, 365 Fifth Avenue, New York, NY 10016, USA
4Biology Doctoral Program, City University of New York Graduate Center, 365 Fifth Avenue, New York, NY 10016 USA
5BIOARRAY Therapeutics Inc., Venture Development Center, UMASS, 100 Morrissey Boulevard, Boston, MA 02125, USA
Correspondence should be addressed to Jimmie E. Fata, jimmie.fata@csi.cuny.edu
and Marcia V. Fournier, marcia.fournier@yahoo.ca
Received 2 November 2011; Revised 16 January 2012; Accepted 17 January 2012
Academic Editor: Andre Van Wijnen
Copyright © 2012 Jimmie E. Fata et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A large amount of data supports the view that PTEN is a bona fide tumor suppressor gene. However, recent evidence suggests
that derailment of cellular localization and expression levels of functional nonmutated PTEN is a determining force in inducing
abnormal cellular and tissue outcomes. As the cellular mechanisms that regulate normal PTEN enzymatic activity resolve, it is
evident that deregulation of these mechanisms can alter cellular processes and tissue architecture and ultimately lead to oncogenic
transformation. Here we discuss PTEN ubiquitination, PTEN complex formation with components of the adherens junction,
PTEN nuclear localization, and microRNA regulation of PTEN as essential regulatory mechanisms that determine PTEN function
independent of gene mutations and epigenetic events.
1. PTEN: A Unique
Dual-Specificity Phosphatase
PTEN (phosphatase and tensin homolog deleted on chromo-
some ten)/MMAC (mutated in multiple advanced cancers)
has been identified simultaneously by two research groups
as a candidate tumor suppressor gene located at 10q23
and encoding 403 amino acids [1, 2]. Another group
identified the same gene in the search for new dual-specific
phosphatases and named it TEP-1 (TGF-β regulated and
epithelial cell-enriched phosphatase) [3]. PTEN is one of
the most common targets of mutation in human cancer,
with a mutation frequency approaching that of the tumor
suppressor gene p53, and it is also mutated in inherited
cancer predisposition disorders. PTEN belongs to the protein
tyrosine phosphatase family with phosphatase activity on
both lipids and proteins. PTEN’s lipid phosphatase catalyzes
the conversion of phosphatidylinositol-(3,4,5)-triphosphate
(PIP3) to phosphatidylinositol-4,5-bisphosphate (PIP2) [4,
5] and plays an important role in the PI3K pathway by
catalyzing degradation of PIP3 generated by PI3K. This
inhibits PI3K downstream targets, mainly PKB-Akt [6–10].
It should be noted, however, that lipid phosphatase atten-
uated or inactive PTEN mutants have been reported to
still retain some tumor suppressing properties [11–15]. So
far there is no report of redundancy for PTEN function,
which could explain the high frequency with which PTEN
inactivation is selected during tumor development [16].
By virtue of PTEN’s ability to attenuate and control the
extent of PI3K signaling, PTEN influences many cellular
functions, including cell growth, survival, proliferation, and
metabolism [8]. PTEN contributes to cell cycle regulation by
blocking cells entering the S-phase of the cell cycle and by
upregulation of p27kip1, which is recruited into the cyclin
E/cdk2 complex [17], and downregulation of cyclin D1 [18].
Exogenous PTEN can suppress the growth of cells with
mutated PTEN alleles [19], but the data of Tamura et al. [20]
also indicates that this tumor suppressor has biological cell
activity unrelated to growth. In contrast tomany other tumor
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suppressors, which appear to have only nuclear roles, PTEN
also appears to function in regulating dynamic cell surface
interactions that involve integrins, FAK, cell migration, and
the cytoskeleton [21–23].
In tumor tissue, proper function of PTEN acts as a
tumor suppressor primarily through the ability to suppress
proliferation and decrease cell survival. The frequent loss
of PTEN function, through deletion, mutations, and/or
decreased expression, is observed in hereditary cancers as
well as sporadic cancers [8]. In many sporadic cancers,
including breast cancer, PTEN is commonly found mutated
at one allele. These monoallelic mutations of PTEN have
been suggested to be as prevalent as p53 mutations found
in most cancers and support the belief that PTEN is a bona
fide tumor suppressor capable of controlling tumor initiation
and progression. Germline mutations of PTEN are evident
in hereditary autosomal dominant cancer syndromes, which
have been collectively termed PTEN hamartoma tumor
syndromes (PHTSs) [24, 25]. Many of these syndromes show
increased risk of cancer occurring in the breast, thyroid, and
endometrial tissues. It becomes apparent that some tissues
are more prone to tumor initiation and progression in the
absence of one PTEN allele, while other tissues often require
both alleles deleted.
In the absence of germline and monoallelic mutations,
PTEN protein levels have been found to be progressively lost
during cancer progression [26]. A number of mechanisms,
other than gene mutation and deletion, contribute to the
loss or the decrease of PTEN protein levels in human
cancers [27–31]. Proposed mechanisms for progressive loss
of PTEN expression, in the absence of mutations, have
been attributed to epigenetic events such as promoter
methylation. Moreover, a large number of studies have
indicated that posttranslational modifications on PTEN
eﬀects the protein’s function, that is, phosphorylation and
ubiquitination decrease PTEN protein levels, while oxidation
and acetylation reduce PTEN activity [32]. Other reports
suggest that E-cadherin expression or function may be an
initiating cause of loss of PTEN expression in cancers, such
as those that frequently occur in breast cancer, where PTEN
expression is lost without identifiable mutations in the PTEN
gene itself. Recently, several reports have indicated that PTEN
shuttles between the nuclear and cytoplasmic compartments
and that PTEN nuclear pool may have function to maintain
genome integrity and cell-cycle control. Furthermore, the
emerging field of microRNAs has revealed that PTEN is
a direct and indirect target of some of these noncoding
RNAs. Here we discuss the regulation of PTEN function
by mechanisms other than gene mutations and epigenetic
events as they relate to cellular function and oncogenic
transformation (Figure 1).
2. Regulation of PTEN Protein Levels
The relevance of downregulated PTEN protein levels, as
opposed to a complete loss of PTEN, is best observed in
mouse models where PTEN is genetically manipulated [33–
37]. In mice heterozygous for PTEN, where PTEN levels are
essentially “50%” less when compared to wild type mice, a
prevalence of tumors in the endometrium, thyroid, prostate,
and liver as well as lymphomas was found. In contrast, mice
with homozygous deletion of PTEN exhibited embryonic
lethality by day 9.5 and displayed defective chorioallantoic
development. Heterozygous deletions of PTEN indicate that
PTEN haploinsuﬃciency predisposes some epithelial cells
to becoming cancerous and this may explain why a large
percentage of human epithelial tumors do not show any signs
of gene mutation or deletion and instead retain wild-type
copies of PTEN. PTEN transgenic mice, that express a range
of PTEN levels (hypomorphs) all lower than wild type levels,
have provided strong evidence that tissue response to PTEN
function is truly dose-dependent [35, 37].
In some cancers, like nonsmall cell lung carcinoma
(NSCLC), where PTEN expression is reduced or lost in 55%–
74% of patients, genetic alteration such as loss of heterozy-
gosity and epigenetic silencing were not good predictors of
PTEN protein levels [29, 30]. With NSCLC, PTEN down
regulation via ubiquitin-mediated degradation appears to
be the primary mechanism of loss of PTEN function. The
E3-ubiquitin ligase NEDD4 (neural precursor cell-expressed,
developmentally downregulated 4-1) is overexpressed in 80%
of NSCLC compared to normal tissue and has been shown
to promote PTEN protein ubiquitin-mediated degradation
and control PTEN stability in mouse tissue [28]. In light
of these findings, NEDD4 overexpression in NSCLC has
been suggested to be the primary factor in driving PTEN
levels down in a large proportion of these cancers. In breast
cancer, where PTEN protein is reduced in as much as 50%
of cases, genetic and epigenetic alterations of the PTEN
locus are rare, again suggesting that PTEN downregulation
is occurring via a posttranslational event [38–40]. Similar
to NSCLC, NEDD4 has been implicated in regulating PTEN
turnover in breast cancer, a process that is inhibited by RAK
phosphorylation of PTEN at Tyr-336 [41]. Unlike the Rak
phosphorylation site on PTEN (Tyr-336), which stabilizes
PTEN protein, phosphorylation at Thr-366, Ser-370, Ser-
380, Thr-382, and Ser-385 has been attributed to attenuating
PTEN stability [42]. It should be noted that Rak, which
exhibits LOH in approximately 30% of breast cancers [43],
has been subsequently termed a bona-fide tumor suppressor
gene in breast cancer [41].
NEDD4 ubiquitin-ligase activity, which downregulates
PTEN protein levels, is enhanced by the small endosomal
PY-motif containing membrane proteins Ndfip1 and Ndfip2
[44]. This suggests that in normal cells the PTEN axis is
balanced by opposing actions of Rak-induced PTEN sta-
bility and Ndfip1/Ndfip2 enhanced NEDD4-directed PTEN
degradation—a shift in favor of NEDD4 activity predisposes
cells to oncogenic transformation. Although strong evidence
points to NEDD4 as an important regulator of PTEN protein
levels in a number of cancer cells (bladder, gastric, and
colorectal) [45, 46], gene knockout studies have challenged
this assumption since in mice lacking NEDD4, PTEN protein
levels remain stable with no evidence of increased stability
in multiple cell types tested [47, 48]. Moreover, evidence
from both in vitro and in vivo studies indicates that PTEN
ubiquitination is still evident even in the absence of NEDD4.
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Figure 1: Mechanisms other than gene mutations and epigenetic silencing that regulate PTEN levels and ultimately its tumor suppressor
function.
Other E3 ligases such as the X-linked inhibitor of apoptosis
protein (XIAP) may also contribute in regulating PTEN
protein levels. XIAP knockdown studies lower PTEN ubiq-
uitination and upregulate PTEN stability, and conversely,
overexpression of XIAP leads to PTEN poly-ubiquitination
and lowered PTEN protein levels [49]. XIAP is a member
of the inhibitor of apoptosis (IAP) family of proteins, and
aside from its ability to act as E3-ligase, it is also capable
of suppressing caspase-dependent cell death and is often
upregulated in cancers [50, 51]. The phosphorylation state of
PTEN also contributes to the regulation of PTEN subcellular
localization and protein levels. PTEN phosphorylation at
serine 380 (Ser-380) and threonines 382/383 (Thr-382/383)
within its C-terminal tail strongly influences PTEN protein
stability and its localization to the cell membrane. Several
kinases, including casein kinase-2, LKB1, RhoA-associated
kinase, the microtubule associated kinase MAT205, and
GSK3β, have been reported to phosphorylate PTEN [52].
In light of the multiple pathways that may regulate PTEN
protein levels, it becomes increasingly evident that these
mechanisms can directly aﬀect tumor initiation and progres-
sion.
3. PTEN and E-cad/MAGI
Calcium-dependent homophilic binding of the adhesion
protein E-cadherin is vital for the cell-cell interaction found
in epithelial tissue, while loss of E-cadherin expression is
associated with transformation and metastatic cancers [53–
55]. It has been demonstrated that PTEN interacts with cell
adhesion molecules such as E-cadherin and MAGI-2 protein
to inhibit migration and proliferation [56–59]. Although
generally considered a cell-adhesion molecule, E-cadherin is
also part of an active signaling network aﬀecting a variety
of cellular processes such as invasion and proliferation [60–
65]. For instance, suppression of E-cadherin expression has
been linked to the downregulation of PTEN expression
and subsequent activity [66], while we have shown that
restoration of E-cadherin increased PTEN protein levels in
E-cadherin null breast cancer cells [67]. A cross-talk exists
between PTEN and E-cadherin since PTEN also stabilizes E-
cadherin at the adherens junction [68].
MAGI (membrane-associated guanylate-kinase inverted)
family members are multidomain scaﬀolding proteins with
multiple sites for protein interaction. There are multiple
splice variants of MAGI; MAGI-1a, MAGI-1b, MAGI-2, and
MAGI-3, where each is expressed in a tissue-specific manner.
MAGI proteins are part of a PDZ subfamily of proteins
called MAGUK (membrane-associated guanylate kinases).
Members of this family, including MAGI-2 and -3, were
shown to directly bind PTEN in yeast two-hybrid screens
[56, 69, 70]. Soon after, mutational analysis showed that
phosphorylation at Thr-382/383 greatly increases aﬃnity of
PTEN for MAGI-2 [58]. Kotelevets et al. put forth the idea
of a signalosome composed of the scaﬀolding protein MAGI,
α- and β-catenin, PTEN, PI3K, and E-cadherin [71]. In this
complex PTEN is believed to be stabilized and protected
from degradation, thus increasing its presence in the cytosol
without aﬀecting mRNA levels [57, 59]. Indeed, the impor-
tance of the association of the E-cadherin via the signalosome
to the cytoskeleton is underscored by the loss of vinculin,
which reduced E-cadherinmediated cell-cell binding [57, 72]
and subsequently decreased PTEN protein levels [57]. PTEN
levels were restored in vin−/− cells by the overexpression of
MAGI-2 or by expressing an E-cadherin-α-catenin fusion
protein. [57]. Our previous work has shown that PTEN is
recruited to cell-cell interactions with E-cadherin, MAGI-
2, and β-catenin in a nonmalignant mammary acini model
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in laminin-rich extracellular matrix. In this model, either
inhibition of E-cadherin function or reduction of PTEN
protein levels abrogated acini organization and proliferation
control suggesting that PTEN roles in cell adhesion and
proliferation may be interconnected [67]. The surprising
sensitivity of mammary cells to the PTEN regulatory node
may explain why it is so low in a variety of solid tumors where
tissue structure is compromised. These findings suggest that
PTEN-dependent changes in PI3K signaling may operate in
conjunction with other E-cadherin-dependent processes to
cause cessation of cell growth.
β-catenin is part of the cadherin-catenin complex and
indirectly connects E-cadherin to the cytoskeleton. Studies
have suggested that β-catenin negatively regulates PTEN
transcription by blocking early growth response gene 1
(Egr1) [66]. Egr1 has been shown to activate PTEN tran-
scription by directly binding to the Egr1 binding motif
in the PTEN promoter [73]. Taken together, a picture
arises depicting the relationship between E-cadherin, PTEN,
MAGI, and loss of cell-cell adhesion in cancer. When present,
E-cadherin stabilizes the adherens junction complex, includ-
ing the signalosome, which sequesters β-catenin at the
plasmamembrane. Thus, β-catenin cannot translocate to the
nucleus and inhibit Egr1 transcription, the eﬀect of which
is continued PTEN transcription. Additionally, PTEN is
protected in the signalosome from proteosomal degradation,
resulting in sustained PTEN protein levels in the cytosol and
subsequently negative regulation of the PI3K/AKT pathway.
Loss of E-cadherin expression in cancer causes disruption
of the signalosome, thus freeing β-catenin and PTEN from
the MAGI scaﬀolding protein. The net eﬀect of this is the
proteosomal degradation of PTEN and the inhibition of
PTEN transcription by β-catenin that has translocated to the
nucleus.
4. Nuclear PTEN
The existence of nuclear PTEN was reported in a number
of cell models including primary neurons and endothelial
cells [74], myoepithelial cells of normal breast ducts [75],
and normal follicular thyroid cells [76]. In general stronger
PTEN nuclear staining has been observed in normal cells
when compared to tumor cells [52] and is thought to
directly correlate with cell diﬀerentiation [77]. The presence
of nuclear PTEN was at first thought to be an artifact based
on immunohistochemical techniques; however, a proposed
role for nuclear PTEN was provided from studies examining
melanoma tumors where a decrease in PTEN nuclear levels
correlated with an increase in the proliferation status of
tumor cells [78]. As well, an investigation with colorectal
adenocarcinoma showed a gradual decrease in nuclear PTEN
expression from normal to subsequent progression stages of
metastasis [79]. Subcellular fractionation and immunocyto-
chemistry studies have confirmed that nuclear translocation
of PTEN in the human breast carcinoma cell line MCF7 was
cell cycle dependant [80]. This cell line has also demonstrated
that a rise in nuclear PTEN level occurs at G0-G1 with a
decrease in nuclear PTEN level in S-phase, indicating nuclear
PTEN to be involved as a cell cycle modulator [81]. Further
studies using the MCF7 cell line found that nuclear PTEN
is required for cell cycle arrest and cytoplasmic PTEN is
required for apoptosis [81]. In contrast to breast cancer cells,
increased level of nuclear PTEN was associated with G2
arrest in melanoma cells instead of G1 [82]. These findings
indicate that nuclear localization of PTEN is associated with
decreased proliferation. These studies and others indicated
that increased nuclear translocation of PTEN is associated
with PTEN tumor-suppressing activity and nuclear PTEN
depletion correlates with increased tumor progression [76,
78, 83, 84] (Figure 2).
The absence of a “true” nuclear localization signal within
PTEN has led to a number of alternative mechanisms
for nuclear entry of PTEN [85]. One mechanism may be
simple diﬀusion, which was found with a GFP-PTEN fusion
protein construct entering the nucleus of HeLa cells [86]. It
should be noted that proteins with molecular mass greater
than 60 kDa are generally prohibited from nuclear entry
by diﬀusion [87, 88]. However, diﬀusion does not explain
the diﬀerential distribution pattern of PTEN in diﬀerenti-
ated/nondividing resting cells and tumor cells. Therefore,
it has been suggested that an active transport system for
PTEN nuclear traﬃcking must exist. One such mechanism
may involve the small GTPase RAN, which is a well-
studied regulator of importin-mediated nuclear transport
[89]. Upon investigating this mechanism, it was found that
a GTPase deficient dominant negative RANQ69L mutant
excluded nuclear entry of PTEN [90]. It should be noted that
this RAN-dependent mechanism of PTEN nuclear import
is also associated with increased cellular apoptosis in the
human glioblastoma cell line U87MG. Another mechanism
of active nuclear import of PTEN may involve the Major
Vault Protein (MVP), which is a carrier molecule involved
in nuclear-cytoplasmic transport of molecules [91]. Evidence
was provided that PTEN binding to MVP promoted nuclear
translocation of PTEN in yeast-two hybrid system [92]. Later
it was confirmed in 293T and HeLa cell lines that it was
a Ca+2-regulated interaction and the binding was specific
between the C2 PTENdomain and the calcium bindingmotif
(EF-hand pair) of MVP [85]. Other mechanisms of PTEN
nuclear import may involve posttranslational modifications
of PTEN. For instance, polyubiquitination of PTEN results
in PTEN degradation, whereas monoubiquitinated PTEN at
K289 undergoes nuclear translocation [45]. Phosphorylation
of PTEN is also another posttranslational modification
of PTEN that has been shown to directly aﬀect nuclear
translocation. The C-terminal domain of PTEN possesses
important phosphorylation sites (Ser-380, Thr-382/383, Ser-
385) which are involved in regulation of PTEN stability,
activity, and localization [42, 93–98]. Phosphorylation of
PTEN at Ser-380 is upregulated during oxidative stress and
associates with an accumulation of nuclear PTEN [98].
The outcome of this accumulation of nuclear PTEN leads
to growth arrest, cellular apoptosis, and a reduction of
reactive oxygen species production [98]. Findings have also
indicated that nuclear localization of PTEN is regulated by
the PI3K pathway. Specifically, cells with dominant negative
Akt mutants or those treated with inhibitors of PI3K mTOR
suppress PTEN nuclear transport, while siRNA silencing
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Figure 2: Cell-characteristics associated with the presence or absence of nuclear PTEN.
for S6K 1/2 (protein kinase) also blocks PTEN nuclear
entry. Together these data suggest that PI3K/Akt/mTOR/S6K
activation leads to PTEN nuclear transport [99]. Finally,
it has been reported that LKB1/CaMKK-(Ca+2/calmodulin-
dependant protein kinase) mediated activation of AMPK
α1/2 can bypass the inhibition of PTEN nuclear entry
achieved with mTOR/S6K downregulation [100] and thus
provides another mechanism for PTEN entering the nucleus.
In seminal work, the functional significance of nuclear
PTEN with regard to proliferation and cell cycle control has
been revealed [101]. In this particular study, it was found that
PTEN nuclear exclusion rather than its phosphatase inacti-
vation was responsible for decreased activation of the APC-
(Anaphase-promoting complex/cyclosome-) CDH1 tumor
suppressor complex. Essentially, nuclear PTEN increases the
activity of APC/C complex and induces its association with
CDH1. APC/C imparts a major regulatory control on the
cell cycle from mitosis to late G1 phase [102, 103], and
its functional activity is maintained through its interaction
with CDC20 and CDH1, while CDH1 activity is restricted
between late mitosis and G1 [104, 105]. The APC-CDH1
complex is essential for cell-cycle regulatory control and
tumor-suppressive activity [101]. By virtue of regulating the
APC/CDH1 complex nuclear PTEN becomes an important
factor in determining cellular outcome and proliferative
status. This is an important finding related to cancer therapy
since, it has been also shown that loss of PTEN sensitizes cells
to pharmacological inhibition of PLK1 and Aurora kinases.
5. Regulation of PTEN by MicroRNAs
MicroRNAs (miRNAs) are short 18–25 nucleotide long
noncoding RNAs involved in posttranscriptional regula-
tion of gene expression [106]. They negatively regulate
target gene expression through complimentary binding to
the 3′ untranslated region (UTR) of mRNAs [107–111].
MicroRNAs have gained importance in development and
progression of several types of cancer that can be explained
by their ability to modulate the expression of gene products
involved in cell migration, invasion, and apoptosis [112,
113]. Overexpression of certain microRNAs like miR-21,
miR-10b, miR-373, and miR-155 has shown to promote
metastasis in cancer whereas downregulation of other miR-
NAs such as miR-31, let-7, miR-146, and miR-193b has been
shown to promote tumor growth, metastasis, and invasion
[114–117].
In 2007,Meng et al. reported overexpression ofmiR-21 in
human hepatocellular cancer using miRNA microarray assay
[27]. Inhibition of miR-21 was accompanied by an increase
in PTEN expression with a decrease in cell migration,
invasion and cell proliferation. Downmodulation of miR-21
also aﬀected the downstream eﬀectors of PTEN such as FAK
phosphorylation as well as MMP-2/9 expression involved in
cell migration and invasion. This original work supported
that PTEN was a direct target of miR-21. Later miR-21
was also reported to be overexpressed in nonsmall cell
lung cancer cells (NSCLCs) compared to adjacent nontumor
cells with an inverse corelation to PTEN expression [118].
NSCLC cell lines transfected with miR-21 inhibitor resulted
in increased luciferase reporter activity for PTEN 3′ UTR,
suggesting that miR-21 binds to the 3′ UTR of PTEN
mRNA. Additionally, an elevation in PTEN protein level was
detected without any eﬀect on PTEN mRNA levels. This
work supported the hypothesis that miR-21 down regulates
posttranscriptional expression of PTEN. Further support
for the role of miR-21 was provided by an in vivo mouse
model in which miR-21 was knocked out. This increased
the expression of several miR-21 target genes including
PTEN [119]. In contrast to these studies, upregulation of
miR-21 in normal and tumor breast cells did not associate
with a detectable change in PTEN levels as determined by
miRNA in situ hybridization techniques [120]. Recent work
has demonstrated that the oncogenicity of miR-21 oncomir
(oncogenic miRNA) could be cell and tissue dependant
and must be contextualized to a particular disease prior to
consideration as a therapeutic target [121].
MicroRNAs other than miR-21 have been shown to be
involved in various biological events and disease through
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PTEN regulation. For instance, MiR-214 is involved in cell
survival [122] and cell apoptosis [123] and has been found to
be overexpressed in gastric cancer cells compared to normal
gastric mucosal cell lines using real-time PCR techniques
[124]. Transient transfection with antisense miRNA-214
oligonucleotides downregulated miR-214 expression with a
significant increase in PTEN expression. Flow cytometry
revealed G1 increases and S-phase decreases in gastric cancer
cells when miRNA-214 was downregulated. PTEN was also
reported to be the direct target of miR-29b in human breast
cancer cells [125]. The breast cancer cell line MDA-MB-
231, which migrates and invades faster than MCF7 cells,
was found to display higher miR-29b levels compared to
MCF7 cells. Inhibition of miR-29b in MDA-MB-231 cells
increased PTEN expression, which promoted apoptosis and
reduced cell migration and invasion. It was also reported
that knockdown of miR-221 and miR-222 in multiple cancer
cell lines upregulated PTEN expression suppressed of AKT
activity with enhanced radio sensitivity in tumor cells [126].
The previous findings have indicated that PTEN is a target
of a number of microRNAs and that cancer cells upregulate
these regulatory RNAs to downregulate the tumor suppressor
characteristics of PTEN.
6. Conclusions
There is ample evidence that the full functionality of
PTEN is modulated by alternative mechanisms beyond gene
mutations and epigenetic processes. For instance a number
of tissue-specific cancers strongly associate with PTEN
deregulation at the gene expression level, changes in PTEN
posttranslational modifications, miss-guided PTEN subcel-
lular localization, and PTEN-specific microRNA upregu-
lation. Determining whether these alternative mechanisms
are causal or a consequence of tumor initiation and pro-
gression or whether they produce tissue-specific eﬀects is
still an ongoing area of important research. Clinically, as
PTEN-regulating pathways become fully resolved, essential
factors will arise, hopefully providing new targets for the
development of novel and eﬀective anticancer therapies and
diagnostic tools.
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